Ocera Therapeutics, Inc. (NASDAQ:OCRX)’s share price gapped down before the market opened on Friday . The stock had previously closed at $0.34, but opened at $1.00. Ocera Therapeutics shares last traded at $1.69, with a volume of 1927879 shares.
OCRX has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Ocera Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. HC Wainwright downgraded Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 price target for the company. in a report on Friday. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $1.69.
Ocera Therapeutics (NASDAQ:OCRX) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. analysts forecast that Ocera Therapeutics, Inc. will post -0.92 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Ocera Therapeutics stock. Virtu KCG Holdings LLC raised its holdings in Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 194.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 213,531 shares of the biopharmaceutical company’s stock after acquiring an additional 141,040 shares during the quarter. Virtu KCG Holdings LLC owned 0.81% of Ocera Therapeutics worth $248,000 as of its most recent filing with the SEC. 20.25% of the stock is owned by institutional investors.
WARNING: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/11/04/ocera-therapeutics-inc-ocrx-shares-gap-down-to-1-00.html.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
What are top analysts saying about Ocera Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ocera Therapeutics Inc. and related companies.